369OBiomarker-integrated study of single agent targeting molecular alterations of PI3KCA, MET, ALK, ROS1, KRAS, NRAS or BRAF in advanced NSCLC: Phase 2 umbrella trial in China (CTONG1505)
Zhou, Q, Zhang, X-C, Tu, H-Y, Gan, B, Wang, B-C, Xu, C-R, Chen, H-J, Zheng, M-Y, Wang, Z, Bai, X-Y, Sun, Y-L, Myers, A, Lv, X, Chakrabcorti, Y, Zhao, S, Yang, J-J, Wu, Y-LVolume:
29
Langue:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy441.002
Date:
November, 2018
Fichier:
PDF, 89 KB
english, 2018